Business Context and Reporting Period
Estrella Immunopharma, Inc. (ESLA) filed a Form 8-K on September 1, 2026, reporting a notification from The Nasdaq Stock Market LLC regarding non-compliance with continued listing standards. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, it explicitly states the following financial conditions:
- Market Value of Listed Securities (MVLS): Below $35,000,000 for 30 consecutive business days (July 21, 2026, through August 31, 2026).
- Stockholders' Equity: Below the alternative listing standard of $2,500,000.
- Net Income: Below the alternative listing standard of $500,000 for the most recently completed fiscal year and two of the last three fiscal years.
Material Changes
The primary material change is the receipt of a formal notice from Nasdaq indicating the company no longer complies with Nasdaq Listing Rule 5550(b)(2) due to insufficient MVLS. Additionally, the company fails to meet alternative standards under Rules 5550(b)(1) and 5550(b)(3).
Outlook, Risks, and Management Commentary
Compliance Period: The company has been granted a 180-day compliance period ending March 1, 2027, to regain compliance. To do so, the MVLS must close at $35,000,000 or more for a minimum of ten consecutive business days.
Management Action: Management intends to monitor MVLS and evaluate options to regain compliance. There is no immediate effect on the trading of common stock.
Risks: There is no assurance the company will regain compliance within the period. Failure to comply by March 1, 2027, will result in written notification of delisting, at which point the company may appeal to a Nasdaq hearings panel.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to assess proximity to the $35,000,000 threshold.
- Review the most recent 10-K or 10-Q to confirm the specific values for stockholders' equity and net income cited in the notice.
- Monitor for any subsequent filings regarding capital raises or strategic actions intended to increase MVLS before the March 1, 2027, deadline.
- Check for any updates on the company's ability to meet alternative listing standards if the MVLS target is not met.